Citizens JMP analyst Jonathan Wolleben downgraded Rallybio (RLYB) to Market Perform from Outperform.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio discontinues RLYB212 program
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating
- Rallybio’s Promising Financial Stability and Strategic Clinical Advancements Drive Buy Rating
- Rallybio Corporation Reports 2024 Financial Results and Progress
- Promising Developments and Financial Stability Support Buy Rating for Rallybio
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue